Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Envoy Medical ( (COCH) ) is now available.
On October 7, 2025, Envoy Medical announced that it received FDA approval to advance its pivotal clinical trial for the Acclaim® cochlear implant to the final stage, following promising three-month data from the initial participants. This approval allows the company to expedite its timeline by three to six months and reduce its capital needs by $10-$15 million, positioning Envoy Medical to potentially redefine the cochlear implant market by addressing the needs of a largely untapped market of U.S. adults who prefer fully implanted devices over traditional external hardware.
The most recent analyst rating on (COCH) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
Spark’s Take on COCH Stock
According to Spark, TipRanks’ AI Analyst, COCH is a Underperform.
Envoy Medical’s stock is severely impacted by poor financial performance, with negative profit margins and high leverage posing significant risks. Technical analysis indicates bearish momentum, and the valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score.
To see Spark’s full report on COCH stock, click here.
More about Envoy Medical
Envoy Medical, Inc. is a hearing health company focused on pioneering fully implanted hearing solutions. The company offers innovative technologies for hearing loss, including the Esteem® active middle ear implant and the investigational Acclaim® cochlear implant, aiming to improve access, usability, and quality of life for individuals with hearing impairments.
Average Trading Volume: 334,534
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.21M
For detailed information about COCH stock, go to TipRanks’ Stock Analysis page.